8 results on '"Sunshine SB"'
Search Results
2. Molecular Biomarkers in Ocular Graft-versus-Host Disease: A Systematic Review.
- Author
-
Bohlen J, Gomez C, Zhou J, Martinez Guasch F, Wandvik C, and Sunshine SB
- Subjects
- Adult, Humans, Biomarkers, Biopsy, Cytokines, Proteomics, Graft vs Host Disease diagnosis
- Abstract
Ocular graft-versus-host disease (oGVHD) affects ~50% of post-stem cell transplant patients and is the only form of GVHD diagnosed without a biopsy. As it must be distinguished from other dry eye diseases, there is a need to identify oGVHD biomarkers to improve diagnosis and treatment. We conducted a systematic review of 19 scholarly articles published from 2018 to 2023 including articles focused on adult patients diagnosed with oGVHD following allogeneic hematopoietic stem cell transplant and used biomarkers as the outcome measure. Articles that were not original investigations or were not published in English were excluded. These clinical investigations explored different molecular oGVHD biomarkers and were identified on 3 October 2023 from the Scopus, PubMed, and Embase databases by using search terms including ocular graft-versus-host disease, biomarkers, cytokines, proteomics, genomics, immune response, imaging techniques, and dry-eye-related key terms. The Newcastle-Ottawa scale for case-control studies was used to assess bias. From the 19 articles included, cytokine, proteomic, lipid, and leukocyte profiles were studied in tear film, as well as ocular surface microbiota and fluorescein staining. Our findings suggest that cytokine profiling is the most studied oGVHD biomarker. Additionally, variations correlating these biomarkers with disease state may lead to a more targeted diagnosis and therapeutic approach. Limitations include language bias, publication bias, and sampling bias, as well as a lack of appropriate controls for included studies. more...
- Published
- 2024
- Full Text
- View/download PDF
No additional results were found in
Catalog
3. Ocular adverse events associated with chimeric antigen receptor T-cell therapy: a case series and review.
- Author
-
Mumtaz AA, Fischer A, Lutfi F, Matsumoto LR, Atanackovic D, Kolanci ET, Hankey KG, Hardy NM, Yared JA, Kocoglu MH, Rapoport AP, Dahiya S, Li AS, and Sunshine SB
- Subjects
- Humans, Cell- and Tissue-Based Therapy, Immunotherapy, Adoptive adverse effects, Retrospective Studies, Male, Female, Adult, Middle Aged, Aged, Hematologic Neoplasms therapy, Hematologic Neoplasms etiology, Lymphoma, Large B-Cell, Diffuse pathology, Receptors, Chimeric Antigen
- Abstract
Background/aims: Chimeric antigen receptor T-cell (CAR T) therapy has been shown to improve the remission rate and survival for patients with refractory haematological malignancies. The aim of this study is to describe ocular adverse effects associated with CAR T therapy in patients with haematological malignancies., Methods: This is a retrospective, single-institution, case series. Patients aged 18 years or older who received standard of care CAR T therapy for relapsed/refractory large B-cell lymphoma with a documented ophthalmic evaluation were included. The primary outcome was clinician ophthalmic examination findings., Results: A total of 66 patients received CAR T-cell therapy from February 2018 to October 2019 with 11 receiving an ophthalmic examination. Eleven patients (n=22 eyes) who received CAR T-cell therapy were included in review. The median time from CAR T-cell infusion date to ocular examination was 57.5 days. The median patient age at the time of examination was 60.5 years. Ten patients had subjective symptoms prompting ophthalmic examination. Two patients reported floaters and photopsias. One patient had worsening ocular graft-versus-host disease. Two patients were identified with possible reactivation of viral infections, including herpes zoster ophthalmicus and regressing acute retinal necrosis., Conclusions: The increasing use of CAR T therapy for malignancies underscores the importance of ophthalmologists and oncologists understanding the potential toxicities associated with its use, particularly ocular toxicities and when to refer for an ophthalmic examination., Competing Interests: Competing interests: None declared., (© Author(s) (or their employer(s)) 2023. No commercial re-use. See rights and permissions. Published by BMJ.) more...
- Published
- 2023
- Full Text
- View/download PDF
4. Can Janus kinase inhibition improve ocular graft versus host disease?
- Author
-
Sajjan S, Tibbs E, Utz M, Rapoport AP, Yared J, Dahiya S, Cao X, Hardy N, and Sunshine SB
- Subjects
- Humans, Janus Kinases, Graft vs Host Disease, Hematopoietic Stem Cell Transplantation
- Abstract
Competing Interests: Declaration of competing interest The authors report no conflict of interest.
- Published
- 2023
- Full Text
- View/download PDF
5. Association of Dietary and Supplementary Calcium Intake With Age-Related Macular Degeneration: Age-Related Eye Disease Study Report 39.
- Author
-
Tisdale AK, Agrón E, Sunshine SB, Clemons TE, Ferris FL 3rd, and Chew EY
- Subjects
- Aged, Aged, 80 and over, Female, Humans, Male, Middle Aged, Proportional Hazards Models, United States, Calcium administration & dosage, Diet, Dietary Supplements, Geographic Atrophy etiology, Wet Macular Degeneration etiology
- Abstract
Importance: Previous studies of the role of dietary and supplementary calcium in age-related macular degeneration (AMD) have produced mixed results, suggesting that supplementation and decreased dietary intake are both harmful., Objective: To evaluate the association of baseline dietary and supplementary calcium intake with progression of AMD., Design, Setting, and Participants: This study involved secondary analyses of participants enrolled in the Age-Related Eye Disease Study (AREDS). The AREDS study (1992-2001) enrolled patients from academic and community-based retinal practices in the United States. Men and women with varying severity of AMD were included. Data analysis for this article occurred from September 2015 to December 2018., Exposures: Baseline self-reported dietary or supplementary calcium intake., Main Outcomes and Measures: Development of late AMD, geographic atrophy (central or noncentral), or neovascular AMD detected on centrally graded baseline and annual fundus photographs., Results: A total of 4751 participants were included (mean [SD] age, 69.4 [5.1] years); 4543 (95.6%) were white, and 2655 (55.9%) were female. Compared with those who were in the lowest quintile, the participants in the highest quintile of dietary calcium intake had a lower risk of developing late AMD (hazard ratio [HR], 0.73 [95% CI, 0.59-0.90]), central geographic atrophy (HR, 0.64 [95% CI, 0.48-0.86]), and any geographic atrophy (HR, 0.80 [95% CI, 0.64-1.00]). The participants in the highest tertile of supplementary calcium intake had a lower risk of developing neovascular AMD (HR, 0.70 [95% CI, 0.50-0.97]) compared with those who did not take calcium supplements. When stratified by sex, women in the highest quintile of dietary calcium intake had a lower risk of developing late AMD (HR, 0.73 [95% CI, 0.56-0.97]) compared with those in the lowest quintile. Women in the highest tertile of calcium supplementation had a lower risk of progression to neovascular AMD (HR, 0.67 [95% CI, 0.48-0.94]) compared with those who did not take calcium supplements. Similar findings were found in men for dietary calcium. Too few men took calcium supplements to allow for analyses., Conclusions and Relevance: In this secondary analysis, higher levels of dietary and supplementary calcium intake were associated with lower incidence of progression to late AMD in AREDS participants. The results may be owing to uncontrolled confounding or chance and should be considered hypothesis development requiring additional study. more...
- Published
- 2019
- Full Text
- View/download PDF
6. Endostatin lowers blood pressure via nitric oxide and prevents hypertension associated with VEGF inhibition.
- Author
-
Sunshine SB, Dallabrida SM, Durand E, Ismail NS, Bazinet L, Birsner AE, Sohn R, Ikeda S, Pu WT, Kulke MH, Javaherian K, Zurakowski D, Folkman JM, and Rupnick M
- Subjects
- Angiogenesis Inhibitors pharmacology, Animals, Antibodies chemistry, Clinical Trials, Phase II as Topic, Female, Heart drug effects, Humans, Male, Mice, Mice, Inbred C57BL, Neovascularization, Pathologic prevention & control, Blood Pressure physiology, Endostatins metabolism, Hypertension metabolism, Hypertension prevention & control, Nitric Oxide metabolism, Vascular Endothelial Growth Factor A antagonists & inhibitors
- Abstract
Antiangiogenesis therapy has become a vital part of the armamentarium against cancer. Hypertension is a dose-limiting toxicity for VEGF inhibitors. Thus, there is a pressing need to address the associated adverse events so these agents can be better used. The hypertension may be mediated by reduced NO bioavailability resulting from VEGF inhibition. We proposed that the hypertension may be prevented by coadministration with endostatin (ES), an endogenous angiogenesis inhibitor with antitumor effects shown to increase endothelial NO production in vitro. We determined that Fc-conjugated ES promoted NO production in endothelial and smooth muscle cells. ES also lowered blood pressure in normotensive mice and prevented hypertension induced by anti-VEGF antibodies. This effect was associated with higher circulating nitrate levels and was absent in eNOS-knockout mice, implicating a NO-mediated mechanism. Retrospective study of patients treated with ES in a clinical trial revealed a small but significant reduction in blood pressure, suggesting that the findings may translate to the clinic. Coadministration of ES with VEGF inhibitors may offer a unique strategy to prevent drug-related hypertension and enhance antiangiogenic tumor suppression. more...
- Published
- 2012
- Full Text
- View/download PDF
7. Poly(β-amino ester)-nanoparticle mediated transfection of retinal pigment epithelial cells in vitro and in vivo.
- Author
-
Sunshine JC, Sunshine SB, Bhutto I, Handa JT, and Green JJ
- Subjects
- Animals, Genetic Therapy methods, Mice, Retinal Diseases genetics, Retinal Diseases metabolism, Nanoparticles administration & dosage, Polymers administration & dosage, Retinal Diseases therapy, Retinal Pigment Epithelium metabolism, Transfection methods
- Abstract
A variety of genetic diseases in the retina, including retinitis pigmentosa and leber congenital amaurosis, might be excellent targets for gene delivery as treatment. A major challenge in non-viral gene delivery remains finding a safe and effective delivery system. Poly(beta-amino ester)s (PBAEs) have shown great potential as gene delivery reagents because they are easily synthesized and they transfect a wide variety of cell types with high efficacy in vitro. We synthesized a combinatorial library of PBAEs and evaluated them for transfection efficacy and toxicity in retinal pigment epithelial (ARPE-19) cells to identify lead polymer structures and transfection formulations. Our optimal polymer (B5-S5-E7 at 60 w/w polymer:DNA ratio) transfected ARPE-19 cells with 44±5% transfection efficacy, significantly higher than with optimized formulations of leading commercially available reagents Lipofectamine 2000 (26±7%) and X-tremeGENE HP DNA (22±6%); (p<0.001 for both). Ten formulations exceeded 30% transfection efficacy. This high non-viral efficacy was achieved with comparable cytotoxicity (23±6%) to controls; optimized formulations of Lipofectamine 2000 and X-tremeGENE HP DNA showed 15±3% and 32±9% toxicity respectively (p>0.05 for both). Our optimal polymer was also significantly better than a gold standard polymeric transfection reagent, branched 25 kDa polyethyleneimine (PEI), which achieved only 8±1% transfection efficacy with 25±6% cytotoxicity. Subretinal injections using lyophilized GFP-PBAE nanoparticles resulted in 1.1±1×10(3)-fold and 1.5±0.7×10(3)-fold increased GFP expression in the retinal pigment epithelium (RPE)/choroid and neural retina respectively, compared to injection of DNA alone (p = 0.003 for RPE/choroid, p<0.001 for neural retina). The successful transfection of the RPE in vivo suggests that these nanoparticles could be used to study a number of genetic diseases in the laboratory with the potential to treat debilitating eye diseases. more...
- Published
- 2012
- Full Text
- View/download PDF
8. Combination of intracranial temozolomide with intracranial carmustine improves survival when compared with either treatment alone in a rodent glioma model.
- Author
-
Recinos VR, Tyler BM, Bekelis K, Sunshine SB, Vellimana A, Li KW, and Brem H
- Subjects
- Animals, Dacarbazine therapeutic use, Disease Models, Animal, Drug Administration Routes, Drug Therapy, Combination methods, Female, Rats, Rats, Inbred F344, Survival Analysis, Temozolomide, Xenograft Model Antitumor Assays, Antineoplastic Agents, Alkylating therapeutic use, Brain Neoplasms drug therapy, Brain Neoplasms mortality, Carmustine therapeutic use, Dacarbazine analogs & derivatives, Glioma drug therapy, Glioma mortality
- Abstract
Background: Local delivery of temozolomide (TMZ) through polymers is superior to oral administration in a rodent glioma model., Objective: We hypothesized that the observed clinical synergy of orally administered TMZ and carmustine (BCNU) wafers would translate into even greater effectiveness with the local delivery of BCNU and TMZ and the addition of radiotherapy in animal models of malignant glioma., Methods: TMZ and BCNU were incorporated into biodegradable polymers that were implanted in F344 rats bearing established intracranial tumors. We used 2 different rodent glioma models: the 9L gliosarcoma and the F98 glioma., Results: In the 9L rodent glioma model, groups treated with the combination of local TMZ, local BCNU, and radiation therapy (XRT) had 75% long-term survivors (defined as animals alive 120 days after tumor implantation), which was superior to the combination of local TMZ and local BCNU (median survival, 95 days; long-term survival, 25%) and the combination of oral TMZ, local BCNU, and XRT (median survival, 62 days; long-term survival, 12.5%). To simulate the effect of this treatment in chemoresistant gliomas, a second rodent model was used with the F98 glioma, a cell line relatively resistant to alkylating agents. F98 glioma cells express high levels of alkyltransferase, an enzyme that deactivates alkylating agents and is the major mechanism of resistance of gliomas. The triple therapy showed a significant improvement in survival when compared with controls (P = .0004), BCNU (P = .0043), oral TMZ (P = .0026), local TMZ (P = .0105), and the combinations of either BCNU and XRT (P = .0378) or oral TMZ and BCNU (P = .0154)., Conclusion: The survival of tumor-bearing animals in the 9L and F98 glioma models was improved with the local delivery of BCNU and TMZ combined with XRT when compared with either treatment alone or oral TMZ, local BCNU, and XRT. more...
- Published
- 2010
- Full Text
- View/download PDF
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.